Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Kerry Chester leads the Antibody Engineering Group at the UCL Cancer Institute. She has over twenty years experience in antibody engineering and antibody phage-display technology. Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets. The work is largely translational; her group designed and manufactured the first single chain Fv antibody (scFv) to enter clinical trials and she is the academic lead of a GMP facility, manufacturing recombinant antibody-based cancer treatments for first-in-human trials. Current projects include bench-to-bedside development of antibodies for use as: cancer imaging agents, antibody drug conjugates, chimeric antigen receptors (CARS) and nano-medicines.